4-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-2-methylbenzonitrile | 1006899-26-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 4-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-2-methylbenzonitrile
• CAS: 1006899-26-8
• 化学式: C₁₃H₁₃N₃O₂
• 分子量: 243.265
• InChiKey: XDZYLYOJHDRLOP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  73.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
  申请人：JAEHNE Gerhard

  公开号：US20090215728A1

  公开（公告）日：2009-08-27

  This invention relates to arylaminoaryl-alkyl-substituted imidazolidone-2,4-diones of formula (I) and also to their physiologically tolerated salts: Wherein R, R′, R1 to R10, A, D, E, G, L and p are as defined herein. The invention also relates to processes for preparing them, pharmaceutical compositions comprising them and their therapeutic use. The compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.

  这项发明涉及公式（I）中的芳基氨基芳基烷基取代的咪唑烷二酮及其生理耐受的盐： 其中R、R'、R1至R10、A、D、E、G、L和p如本文所定义。该发明还涉及制备它们的方法、包含它们的药物组合物以及它们的治疗用途。这些化合物适用于例如作为抗肥胖药物和治疗心脏代谢综合征。
• NON-STEROIDAL ANTIANDROGENS AND SELECTIVE ANDROGEN RECEPTOR MODULATORS WITH A PYRIDYL MOIETY
  申请人：LABRIE Fernand

  公开号：US20150175576A1

  公开（公告）日：2015-06-25

  Compounds having the structure or their salts: are used to treat or reduce the likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia, male baldness, muscle atrophy and weakness, sarcopenia, male hypogonadism, erectile dysfunction, female sexual dysfunction and osteoporosis. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Combinations with other active pharmaceutical agents are also disclosed.

  具有以下结构或其盐的化合物：用于治疗或减少患雄激素依赖性疾病的可能性，如前列腺癌、良性前列腺增生、多囊卵巢综合征、痤疮、多毛症、皮脂溢、雄激素性脱发、男性秃头、肌肉萎缩和无力、肌肉质量减少、男性性腺功能减退、勃起功能障碍、女性性功能障碍和骨质疏松症。它们可以与药学上可接受的稀释剂或载体一起配制，或以任何药物剂量形式制成。还披露了与其他活性药物成分的组合。
• IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT
  申请人：Bigg Dennis

  公开号：US20120095068A1

  公开（公告）日：2012-04-19

  The subject matter of the present application is novel imidazolidine-2,4-dione derivatives of general formula (I) in which R 1 , R 2 , R 3 and X are variables. These products have an anti-proliferative activity. They are particularly advantageous for treating pathological conditions and diseases associated with abnormal cell proliferation, such as cancers. The invention also relates to pharmaceutical compositions containing said products and to the use thereof for preparing a medicament.

  本申请的主题是一种新型咪唑啉-2,4-二酮衍生物，其通式为(I)，其中R1、R2、R3和X为变量。这些产品具有抗增殖活性。它们特别适用于治疗与异常细胞增殖相关的病理条件和疾病，如癌症。该发明还涉及含有上述产品的药物组合物以及用于制备药物的使用。
• [DE] ARYLAMINOARYL-ALKYL-SUBSTITUIERTE IMIDAZOLIDIN-2,4-DIONE, VERFAHREN ZU IHRER HERSTELLUNG, DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL UND IHRE VERWENDUNG<br/>[EN] ARYLAMINOARYL-ALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, PROCESSES FOR PREPARING THEM, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THEIR USE<br/>[FR] IMIDAZOLIDIN-2,4-DIONE ARYLAMINOARYL-ALKYL-SUBSTITUÉE, SON PROCÉDÉ DE FABRICATION, MÉDICAMENT CONTENANT CE COMPOSÉ ET SON UTILISATION
  申请人：SANOFI AVENTIS

  公开号：WO2008017381A1

  公开（公告）日：2008-02-14

  (DE) Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung. Die Erfindung betrifft Verbindungen der Formel I, worin die Reste R und R' A, D, E, G, L, p und Rl bis RIO die angegebenen Bedeutungen haben, sowie deren physiologisch verträgliche Salze. Die Verbindungen eignen sich z.B. als Antiadiposita und zur Behandlung des cardio-metabolischen Syndroms.(EN) Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use. The invention relates to compounds of the formula I in which the radicals R and R', A, D, E, G, L, p and R1 to R1O have the stated definitions, and also to their physiologically tolerated salts. The compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.(FR) L'invention concerne des composés de formule I, dans laquelle les radicaux R et R', A, D, E, G, L, p et R1 à R10 ont les significations données, ainsi que leurs sels physiologiquement acceptables. Les composés s'utilisent par ex. comme agent anti-obésité et pour le traitement du syndrome cardio-métabolique.

  （德）芳氨基芳烷基取代的二氢咪唑-2,4-二酮，制备它们的方法，含有这些化合物的药物以及它们的用途。本发明涉及式I的化合物，其中基团R和R'，A、D、E、G、L、p及R1至RIO具有所述的定义，以及它们的生理上可耐受的盐。这些化合物适用于例如作为抗脂肪过度积累剂，用于治疗心肌代谢综合征。 （英文参考翻译）芳氨基芳烷基取代的二氢咪唑-2,4-二酮，制备它们的方法，含有这些化合物的药物以及它们的用途。本发明涉及式I的化合物，其中基团R和R'，A、D、E、G、L、p及R1至RIO具有所述的定义，以及它们的生理上可耐受的盐。这些化合物适用于例如作为抗脂肪过度积累剂，用于治疗心肌代谢综合征。
• ARYLAMINOARYL-ALKYL-SUBSTITUIERTE IMIDAZOLIDIN-2,4-DIONE, VERFAHREN ZU IHRER HERSTELLUNG, DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL UND IHRE VERWENDUNG
  申请人：Sanofi-Aventis

  公开号：EP2061767A1

  公开（公告）日：2009-05-27